Pamela Munster

MD

Medical oncologist

  • Education

    University of Bern, 1989

  • Residencies

    Indiana University School of Medicine, Internal Medicine, 1996

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, Hematology-Oncology, 2000

  • Academic Title

    Professor

  • Languages

    French

    German

    Italian

Conditions I specialize in

Carol Franc Buck Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

(415) 353-7070
M-F, 8 a.m. - 5 p.m.

Hereditary Cancer Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

(415) 353-9797

My reviews

4.8

Overall Experience
103 Reviews
I count myself among the luckiest people on earth to have a caregiver such as Dr Munster. She is brilliant a top professional and a warm and compassionate human being. They don't make them like her anymore.
Explained things in a way that was easy to understand
103 Reviews
Did the doctor pay attention to your concerns
103 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
98 Reviews
Knew the important information about your medical history
103 Reviews
The provider showed respect for what you had to say
103 Reviews
The provider spent enough time with me
103 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...

A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related

Recruiting

Decorative Caduceus

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects...

Recruiting

Decorative Caduceus

9-ING-41 in Patients With Advanced Cancers

The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.

Recruiting

Decorative Caduceus

Study of ORIC-101 in Combination With Anticancer Therapy

RP2D as determined by 3+3 dose escalation design

Recruiting

Decorative Caduceus

AO-176 in Multiple Solid Tumor Malignancies

Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.

Recruiting

Decorative Caduceus

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Recruiting

Decorative Caduceus

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

ORR is defined as the proportion of patients with either confirmed complete or partial response (as per RECIST version 1.1) as best overall response over the total population.

Recruiting

Contact me

Providers on my team

Share